Bone marrow angiotensin AT2 receptor deficiency aggravates atherosclerosis development by eliminating macrophage liver X receptor-mediated anti-atherogenic actions

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 936-946

  Kato, Taku ^a   Kawahito, Hiroyuki ^a   Kishida, Sou ^a   Irie, Daisuke ^a   Wakana, Noriyuki ^a   Kikai, Masakazu ^a   Takata, Hiroki ^a   Ogata, Takehiro ^a   Ueyama, Tomomi ^a   Matoba, Satoaki ^a   Yamada, Hiroyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Angiotensin; Atherosclerosis; Liver X receptor; Macrophage; Receptor

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ABC TRANSPORTER A1; ANGIOTENSIN 2 RECEPTOR; APOLIPOPROTEIN E; ARGINASE 1; CD206 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHOLESTEROL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LYMPHOCYTE ANTIGEN; MESSENGER RNA; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2-MERCAPTOACETATE; ABCA1 PROTEIN, MOUSE; CCR7 PROTEIN, MOUSE; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; THIOGLYCOLIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW; BONE MARROW CELL; CHOLESTEROL DIET; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNOHISTOCHEMISTRY; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL POLARITY; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; BIOLOGICAL TRANSPORT; BONE MARROW; CELL POLARITY; CHOLESTEROL; GENE EXPRESSION REGULATION; INFLAMMATION; LIVER X RECEPTORS; MACROPHAGES, PERITONEAL; MICE, INBRED C57BL; ORPHAN NUCLEAR RECEPTORS; PHENOTYPE; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, CCR7; THIOGLYCOLATES;

EID: 84952883817     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314561138     Document Type: Article

References (40)

1. Daugherty A, Manning MW, Cassis LA., Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-1612.
2. Weiss D, Kools JJ, Taylor WR., Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-454.
3. 1A receptor. Circulation 2004; 110: 3849-3857.
4. Rodgers KE, Xiong S, Steer R, et al. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000; 18: 287-294.
5. Petnehazy T, Stokes KY, Wood KC, et al. Role of blood cell-associated AT1 receptors in the microvascular responses to hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006; 26: 313-318.
6. Fukuda D, Sata M, Ishizaka N, et al. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 90-96.
7. Tsubakimoto Y, Yamada H, Yokoi H, et al. Bone marrow angiotensin AT1 Receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler Thromb Vasc Biol 2009; 29: 1529-1536.
8. Mosser DM, Edwards JP., Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
9. Johnson JL, Newby AC., Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol 2009; 20: 370-378.
10. Sica A, Mantovani A., Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 2012; 122: 787-795.
11. Leitinger N, Schulman IG., Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol 2013; 33: 1120-1126.
12. Khallou-Laschet J., Macrophage plasticity in experimental atherosclerosis. PLoS One 2010; 5: e8852.
13. Yamamoto S, Yancey PG, Zuo Y, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 2856-2864.
14. Ma LJ, Corsa BA, Zhou J, et al. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol 2011; 300: F1203-1213.
15. Lukasova M, Malaval C, Gille A, et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011; 121: 1163-1173.
16. Tangirala RK, Bischoff ED, Joseph SB, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002; 99: 11896-11901.
17. Rigamonti E, Chinetti-Gbaguidi G, Staels B., Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008; 28: 1050-1059.
18. Calkin AC, Tontonoz P., Liver X receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1513-1518.
19. Im SS, Osborne TF., Liver X receptors in atherosclerosis and inflammation. Circ Res 2011; 108: 996-1001.
20. Nagy L, Szanto A, Szatmari I, et al. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. Physiol Rev 2012; 92: 739-789.
21. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7: 161-171.
22. Feig JE, Pineda-Torra I, Sanson M, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest 2010; 120: 4415-4424.
23. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-219.
24. Korach-André M, Archer A, Gabbi C, et al. Liver X receptors regulate de novo lipogenesis in a tissue-specific manner in C57BL/6 female mice. Am J Physiol Endocrinol Metab 2011; 301: E210-222.
25. Pascual-García M, Carbó JM, León T, et al. Liver X receptors inhibit macrophage proliferation through downregulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4. J Immunol 2011; 186: 4656-4667.
26. Levin N, Bischoff ED, Daige CL, et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005; 25: 135-142.
27. Bradley MN, Hong C, Chen M, et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J Clin Invest 2007; 117: 2337-2346.
28. Cui T, Nakagami H, Iwai M, et al. Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc Res 2001; 49: 863-871.
29. Alvarez SE, Seguin LR, Villarreal RS, et al. Involvement of c-Src tyrosine kinase in SHP-1 phosphatase activation by Ang II AT2 receptors in rat fetal tissues. J Cell Biochem 2008; 105: 703-711.
30. Wu L, Iwai M, Li Z, et al. Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol 2004; 18: 666-678.
31. Horiuchi M, Hayashida W, Kambe T, et al. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272: 19022-19006.
32. Shenoy UV, Richards EM, Huang XC, et al. Angiotensin II type 2 receptor-mediated apoptosis of cultured neurons from newborn rat brain. Endocrinology 1999; 140: 500-509.
33. Horsley V, Pavlath GK., NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 2002; 156: 771-774.
34. Ritter O, Schuh K, Brede M, et al. AT2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J 2003; 17: 283-285.
35. Imayama I, Ichiki T, Patton D, et al. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 2008; 51: 1631-1636.
36. Takata Y, Chu V, Collins AR, et al. Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: A novel atherosclerotic effect of angiotensin II. Circ Res 2005; 97: e88-96.
37. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47: 5995-6008.
38. Rehman A, Leibowitz A, Yamamoto N, et al. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2012; 59: 291-299.
39. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008; 118: 2523-2532.
40. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2010; 55: 924-931.